Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with MSK histologically confirmed hematologic malignancy
- Scheduled for autologous or allogenic HCT at MSKCC
- ≥21 years old
- ECOG performance status of 0 or 1
- Completion of baseline CPET
- Willing to comply with protocol related procedures
Exclusion Criteria:
Any of the following absolute contraindications to cardiopulmonary exercise testing
- Acute myocardial Infarction (within 3-5 days of any planned study procedures)
- Unstable angina
- Uncontrolled arrhythmia causing symptoms or hemodynamic compromise
- Recurrent syncope
- Active endocarditis
- Acute myocarditis or pericarditis
- Symptomatic severe aortic stenosis
- Uncontrolled heart failure
- Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures
- Thrombosis of lower extremities
- Suspected dissecting aneurysm
- Uncontrolled asthma
- Pulmonary edema
- Respiratory failure
- Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
- Presence of any other concurrent, actively treated malignancy;
- History of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer);
- Room air desaturation at rest ≤85%
- Mental impairment leading to inability to cooperate
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
functional performance testing
This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT.
In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VO2peak
Time Frame: 1 year
|
is a measure determined by the CPET
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15-274
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
NCT05208853Not yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell Lymphoma
-
NCT00992446CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma
-
NCT01000753CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular Lymphoma
-
NCT02142530CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell Lymphoma
-
NCT01693614CompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
-
NCT05907447Not yet recruitingLymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-Type
-
NCT06026319RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma
-
NCT06563596RecruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Refractory Lymphoma | Relapsed Lymphoma
-
NCT03520920CompletedFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma
-
NCT02756247CompletedLymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma
Clinical Trials on Symptom-limited cardiopulmonary exercise test (CPET)
-
NCT03993522TerminatedCoronary Occlusion
-
NCT02435472CompletedLocalized Prostate Cancer | Active Surveillance for Prostate Cancer
-
NCT04195061CompletedInsulin Resistance | Overweight and Obesity
-
NCT05353127CompletedColorectal Cancer | Surgery | Colorectal Neoplasms Malignant
-
NCT02458703UnknownAsthma | COPD | Hereditary Hemorrhagic Telangiectasia | Pulmonary Arteriovenous Malformations
-
NCT02235441TerminatedPathologically Proven Gastrointestinal Malignancy | Plan of Care Must Include Chemoradiation
-
NCT02669212CompletedChronic Fatigue Syndrome
-
NCT06780514Recruiting